Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.
- Stereotactic ablative radiotherapy (SABR)
- innovative therapy
- non-small cell lung cancer (NSCLC)
- stage I lung cancer
- stereotactic body radiation therapy
ASJC Scopus subject areas
- Cancer Research